---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-036151"
form_type: "8-K"
ticker: "VKTX"
cik: "0001607678"
company_name: "Viking Therapeutics, Inc."
filed_at: "2024-03-26T23:59:59+00:00"
generated_at: "2026-06-04T07:52:53.697097+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Viking Therapeutics Reports Positive Phase 1 Results for Oral VK2735 with Up to 5.3% Weight Loss

## Summary
- Up to 5.3% mean weight loss from baseline after 28 days in Phase 1 MAD trial of oral VK2735
- Placebo-adjusted mean weight loss up to 3.3%; up to 57% of treated subjects achieved ≥5% weight loss vs 0% placebo
- VK2735 well-tolerated with low GI adverse events; no serious adverse events reported
- Company plans Phase 2 trial in obesity for second half of 2024

## SEC filing metadata
- accession: 0000950170-24-036151
- form_type: 8-K
- ticker: VKTX
- cik: 0001607678
- company_name: Viking Therapeutics, Inc.
- filed_at: 2024-03-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607678/000095017024036151/0000950170-24-036151-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607678/000095017024036151/vktx-20240326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-036151
- JSON: https://secwatch.observer/filing/0000950170-24-036151.json
- Plain text: https://secwatch.observer/filing/0000950170-24-036151.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.